Nav: Home

Experts highlight ebola vaccine progress and suggest next steps

August 10, 2018

WHAT:

Despite promising advances, important scientific questions remain unanswered in the effort to develop a safe and effective Ebola vaccine, according to members of an international Ebola research consortium. In a Viewpoint published in The Lancet, the experts review the current field of Ebola vaccine candidates and clinical trials and highlight key gaps in knowledge that need to be addressed by future research.

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, are among the Viewpoint's authors. All authors are with the Partnership for Research on Ebola VACcination (PREVAC). In addition to NIAID, the partnership, established in 2017, comprises experts from the French National Institute of Health and Medical Research (Inserm), the London School of Hygiene & Tropical Medicine (LSHTM), the West African Clinical Research Consortium and their collaborators. PREVAC is currently conducting a Phase 2 clinical trial in Guinea, Liberia, Sierra Leone and Mali to evaluate three Ebola vaccination strategies in people one year and older.

Ebola virus disease remains a public health threat--the Democratic Republic of the Congo (DRC) already has experienced two Ebola outbreaks in 2018--underscoring the need for continued efforts to develop an effective vaccine. The authors note that 36 trials of Ebola vaccine candidates have been completed and another 14 are active, according to clinicaltrials.gov. The rVSV-ZEBOV experimental vaccine, which has been deployed in the DRC, is the only candidate with some clinical efficacy data, which were obtained in a clinical trial in Guinea conducted during the 2014-2016 Ebola outbreak in Guinea.

After reviewing the status of four additional vaccine candidates under study (Ad26.ZEBOV, MVA-BN-Filo, chAd3-EBO-Z, and the GamEvac-Combi vaccine), the authors highlight areas where more research is required. Specifically, they note the need for more data in pregnant women, children and immunocompromised populations, including people infected with HIV and the elderly. Additionally, they say more research is needed on the durability and rapidity of immune responses generated by various vaccine approaches. The experts also call for studies to identify reliable correlates of protection (the specific and measurable part of an immune response that would indicate a person is protected from Ebola) as well as large-scale trials to fully evaluate the safety and efficacy of experimental vaccines.

The authors conclude by underscoring the value of embedding social science research in clinical trial design to help build trust and engagement with the affected communities. They note that in addition to the need to investigate various vaccines and vaccination strategies to respond more effectively to future outbreaks, improving the global capacity to conduct clinical research and forming collaborative partnerships, such as PREVAC, are crucial for success.
-end-
ARTICLE:

Y Lévy et al. Prevention of Ebola virus disease through vaccination: where we are in 2018. The Lancet DOI: 10.1016/S0140-6736(18)31710-0 (2018).

WHO:

NIAID Director Anthony S. Fauci, M.D., is available for comment. H. Clifford Lane, M.D., deputy director for Clinical Research and Special Projects at NIAID and an author of the viewpoint, is also available.

CONTACT:

To schedule interviews, please contact Jennifer Routh, (301) 402-1663, jennifer.routh@nih.gov.

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIH...Turning Discovery Into Health ®

NIH/National Institute of Allergy and Infectious Diseases

Related Ebola Articles:

Ebola survivors have a 'unique' retinal scar
Researchers from the University of Liverpool have conducted a study of Ebola survivors to determine if the virus has any specific effects on the back on the eye using an ultra widefield retinal camera.
Ebola: Lives to be saved with new management approach
Ebola outbreaks are set to be managed quickly and efficiently -- saving lives -- with a new approach developed by an international team of researchers, including the University of Warwick, which helps to streamline outbreak decision-making.
Ebola vaccines provide immune responses after 1 year
Immune responses to Ebola vaccines at one year after vaccination are examined in a new study appearing in the March 14 issue of JAMA.
New scoring system predicts Ebola severity
While Ebola virus disease (EVD) is notorious for being one of the world's most deadly infections, it actually has a wide range of outcomes, where asymptomatic presentation may be as common as fatality.
Could co-infection with other viruses affect the survival of those with Ebola virus?
Could co-infection with other viruses have a detrimental affect on Ebola survival, and why did some show Ebola symptoms without having the virus?
Antimalarial being tested as possible Ebola virus drug
The National Center for Advancing Translational Sciences (NCATS) recently awarded $596,533.00 to Collaborations Pharmaceuticals, Inc.
Ebola map may help prepare for future outbreaks
To be prepared for new Ebola virus disease cases, it is fundamental to start by identifying the range of the virus and the regions that are more favorable for its propagation.
Sexual transmission of Ebola likely to impact course of outbreaks
Sexual transmission of the Ebola virus could have a major impact on the dynamics of the disease, potentially reigniting an outbreak that has been contained by public health interventions, according to research by University of Georgia ecologists just published in the Royal Society journal Biology Letters.
Ebola vaccine: Promising phase I trials
The clinical phase I trial of a potential vaccine against the dreaded Ebola virus has been successfully completed at four partner sites in Africa and Europe.
Improving treatments for post-Ebola syndrome sufferers
Researchers from the University of Liverpool and the King's Sierra Leone Partnership are to present new findings into post-Ebola syndrome at a major European conference this week.

Related Ebola Reading:

Ebola: The Natural and Human History of a Deadly Virus
by David Quammen (Author)

Ebola: How a People's Science Helped End an Epidemic (African Arguments)
by Paul Richards (Author)

Epidemic: Ebola and the Global Scramble to Prevent the Next Killer Outbreak
by Reid Wilson (Author)

The Hot Zone: The Terrifying True Story of the Origins of the Ebola Virus
by Richard Preston (Author)

Ebola: A novel of the first outbreak, by a doctor who was there
by Dr. William Close (Author), Joel Breman (Foreword)

Inferno: A Doctor's Ebola Story
by Steven Hatch M.D. (Author)

Ebola: Behind the Mask
by Anna Simon (Author), Andy Dennis (Author)

Pandemic: Tracking Contagions, from Cholera to Ebola and Beyond
by Sonia Shah (Author)

Level 4: Virus Hunters of the CDC - Tracking Ebola and the World's Deadliest Viruses
by Joseph B. McCormick (Author), Susan Fisher-Hoch (Author), Leslie Alan Horvitz (Author)

The Ebola Survival Handbook: An MD Tells You What You Need to Know Now to Stay Safe
by Joseph Alton (Author)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

The Story Behind The Numbers
Is life today better than ever before? Does the data bear that out? This hour, TED speakers explore the stories we tell with numbers — and whether those stories portray the full picture. Guests include psychologist Steven Pinker, economists Tyler Cowen and Michael Green, journalist Hanna Rosin, and environmental activist Paul Gilding.
Now Playing: Science for the People

#487 Knitting in PEARL
This week we're discussing math and things made from yarn. We welcome mathematician Daina Taimina to the show to discuss her book "Crocheting Adventures with Hyperbolic Planes: Tactile Mathematics, Art and Craft for all to Explore", and how making geometric models that people can play with helps teach math. And we speak with research scientist Janelle Shane about her hobby of training neural networks to do things like name colours, come up with Halloween costume ideas, and generate knitting patterns: often with hilarious results. Related links: Crocheting the Hyperbolic Plane by Daina Taimina and David Henderson Daina's Hyperbolic Crochet blog...